TrialESMO open2025

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.

F Lynce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.